Boston, Mass., May 1, 2018 – The Institute for Clinical and Economic Review (ICER) has appointed new members to each of its three independent evidence appraisal councils: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC).
The new members join the councils of regionally-based experts who represent a broad range of perspectives including medical ethics, patient advocacy and engagement, outcomes research, health economics, technology assessment, and clinical practice. Council members are chosen based on their expertise in reviewing and applying medical evidence in a variety of contexts and are not selected based on their specific expertise in a given clinical area. All members must meet strict conflict of interest criteria to participate in ICER’s meetings.
The newest members of each of the panels include:
Annette Langer-Gould, MD, PhD
Regional Lead for Clinical and Translational Neuroscience
Southern California Permanente Medical Group, Kaiser Permanente
Associate Professor of Medicine
University of California San Francisco
Elizabeth J. Murphy, MD, DPhil
Professor of Clinical Medicine, University of California San Francisco
Chief, Division of Endocrinology and Metabolism, Zuckerberg San Francisco General Hospital
Ingram Associate Professor of Cancer Research
Vanderbilt University School of Medicine
Elbert Huang, MD, MPH
Professor of Medicine
Director, Center for Chronic Disease Research and Policy
University of Chicago
Timothy McBride, PhD
Co-Director, Center for Health Economics and Policy
Professor, Brown School
Washington University in St. Louis
Timothy Wilt, MD, MPH
Professor of Medicine
Director, Minnesota Evidence-based Synthesis Program
Minneapolis VA Center for Chronic Disease Outcomes Research
Stuart A. Winston, DO
Physician Lead: Patient Experience, Quality Improvement
Integrated Health Associates
St. Joseph Mercy Health System
New England CEPAC
New York Academy of Medicine
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.